Ruxolitinib + Duvelisib for Lymphoma
Trial Summary
The trial protocol does not specify if you must stop taking your current medications. However, you may need to stop using certain medications that strongly affect liver enzymes (CYP3A) at least 2 weeks before starting the trial. It's best to discuss your current medications with the trial team.
Duvelisib has been shown to be effective in treating certain types of lymphoma, such as chronic lymphocytic leukemia and follicular lymphoma, especially after other treatments have failed. It works by blocking specific proteins that help cancer cells grow. Additionally, studies suggest that combining duvelisib with other drugs can enhance its effectiveness in fighting cancer.
12345Ruxolitinib is generally well tolerated, but common side effects include mild to moderate anemia (low red blood cell count), thrombocytopenia (low platelet count), and lymphopenia (low white blood cell count), which are usually manageable with dosage adjustments. Rarely, it can cause skin reactions. There is no specific safety data available for the combination with Duvelisib, but these findings provide some insight into the safety of Ruxolitinib alone.
678910The combination of Ruxolitinib and Duvelisib is unique because Ruxolitinib targets the JAK-STAT pathway, which is often overactive in certain lymphomas, potentially enhancing the effectiveness of treatment by inducing cancer cell death and inhibiting tumor growth.
1112131415Eligibility Criteria
Adults over 18 with certain types of T-cell lymphoma or leukemia, who've had at least one prior therapy (treatment-naive allowed for some conditions), can join this trial. They must be able to swallow pills, have a specific level of organ function, and not be pregnant or breastfeeding. Contraception is required during the study.Inclusion Criteria
Exclusion Criteria
Participant Groups
- Relapsed or refractory chronic lymphocytic leukemia (CLL)
- Relapsed or refractory small lymphocytic lymphoma (SLL)